EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway

Ying Zhou, Xiyu Du, Qianyu Wang, Shilin Xiao, Juan Zhi, Huibin Gao, Dong Yang iD

Mediators of Inflammation · 2023

DOI: 10.1155/2023/3695469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, 2023. Verfasst von Ying Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shijingshan District, B…. Hauptthemen laut MEDLINE: Dexmedetomidine, Asthma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences, Peking Union Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a common respiratory disease characterized by chronic airway inflammation. Dexmedetomidine (DEX), a highly selective α2 adrenergic receptor agonist, has been shown to participate in regulating inflammatory states and thus exert organ protective actions. However, the potential of DEX in asthma is still unknown. This study is aimed at investigating the role of DEX in a mouse model of house dust mite- (HDM-) induced asthma and exploring its underlying mechanism. Here, we found that DEX treatment significantly ameliorated airway hyperresponsiveness, airway inflammation, and airway remodeling in the asthmatic mice, which were similar to the efficacy of the reference anti-inflammatory drug dexamethasone. In addition, DEX reversed the increased expression of toll-like receptor 4 (TLR4) and its downstream signaling adaptor molecule nuclear factor-κB (NF-κB) in the lung tissue of asthmatic mice. Furthermore, these protective effects of DEX were abolished by yohimbine, an α2 adrenergic receptor antagonist. These results indicate that DEX is capable of ameliorating airway inflammation and remodeling in asthmatic mice, and this protective effect is associated with the inhibition of the TLR4/NF-κB signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineAsthmaRatsMiceAnimalsNF-kappa BToll-Like Receptor 4Airway RemodelingDisease Models, AnimalRats, Sprague-DawleySignal TransductionInflammation

Substanzen

NF-kappa BDexmedetomidineToll-Like Receptor 4Tlr4 protein, mouseTlr4 protein, rat

Autor:innen und Institutionen

  • Department of Anesthesiology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shijingshan District, Beijing, China 100144.

ORCID-Profile: Dong Yang

Förderung

  • Chinese Academy of Medical Sciences
  • Peking Union Medical College

Zitieren

APA

Zhou, Y., Du, X., Wang, Q., Xiao, S., Zhi, J., Gao, H., & Yang, D. (2023). Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway. Mediators of Inflammation. https://doi.org/10.1155/2023/3695469

Vancouver

Zhou Y, Du X, Wang Q, Xiao S, Zhi J, Gao H, et al. Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway. Mediators of Inflammation. 2023. doi:10.1155/2023/3695469

BibTeX
@article{Zhou2023,
  author = {Zhou, Ying and Du, Xiyu and Wang, Qianyu and Xiao, Shilin and Zhi, Juan and Gao, Huibin and Yang, Dong},
  title = {Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway},
  journal = {Mediators of Inflammation},
  year = {2023},
  doi = {10.1155/2023/3695469}
}
Kostenlos starten →